DE60237145D1 - Chinazolinderivate - Google Patents

Chinazolinderivate

Info

Publication number
DE60237145D1
DE60237145D1 DE60237145T DE60237145T DE60237145D1 DE 60237145 D1 DE60237145 D1 DE 60237145D1 DE 60237145 T DE60237145 T DE 60237145T DE 60237145 T DE60237145 T DE 60237145T DE 60237145 D1 DE60237145 D1 DE 60237145D1
Authority
DE
Germany
Prior art keywords
quinazoline derivatives
agent
compound
theprophylaxis
racemate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237145T
Other languages
German (de)
English (en)
Inventor
Yasunori Kitano
Eiji Kawahara
Tsuyoshi Suzuki
Daisuke Abe
Masahiro Nakajou
Naoko Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of DE60237145D1 publication Critical patent/DE60237145D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60237145T 2001-02-21 2002-02-21 Chinazolinderivate Expired - Lifetime DE60237145D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001045827 2001-02-21
JP2001353525 2001-11-19
PCT/JP2002/001575 WO2002066445A1 (en) 2001-02-21 2002-02-21 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
DE60237145D1 true DE60237145D1 (de) 2010-09-09

Family

ID=26609852

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237145T Expired - Lifetime DE60237145D1 (de) 2001-02-21 2002-02-21 Chinazolinderivate

Country Status (10)

Country Link
US (2) US7294629B2 (OSRAM)
EP (1) EP1369418B1 (OSRAM)
JP (1) JP4285996B2 (OSRAM)
KR (1) KR100861486B1 (OSRAM)
CN (1) CN1264824C (OSRAM)
AT (1) ATE475652T1 (OSRAM)
CA (1) CA2442742A1 (OSRAM)
DE (1) DE60237145D1 (OSRAM)
TW (1) TWI309647B (OSRAM)
WO (1) WO2002066445A1 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
PL1667992T3 (pl) * 2003-09-19 2007-05-31 Astrazeneca Ab Pochodne chinazoliny
WO2005028470A1 (en) * 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US20070043010A1 (en) * 2003-09-25 2007-02-22 Astrazeneca Uk Limited Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
CA2547284A1 (en) * 2003-11-28 2005-06-09 Mitsubishi Pharma Corporation Quinazoline derivative and process for producing the same
EP1713781B1 (en) 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
RS52119B (sr) 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
EP1792898A1 (en) * 2004-09-01 2007-06-06 Mitsubishi Pharma Corporation Molecular chaperone function regulator
US7947676B2 (en) 2004-12-14 2011-05-24 Astrazeneca Ab Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
CA2599328C (en) 2005-02-23 2012-04-17 Shionogi & Co., Ltd. Quinazoline derivative having tyrosine kinase inhibitory activity
MX2007010399A (es) 2005-02-26 2007-09-25 Astrazeneca Ab Derivados de quinazolina en la forma de inhibidores de cinasa de tirosina.
JP4993205B2 (ja) * 2005-03-30 2012-08-08 塩野義製薬株式会社 チロシンキナーゼ阻害作用を有するピリミジン誘導体
JP2009508918A (ja) 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 癌治療のためのｅｒｂＢ受容体チロシンキナーゼ阻害剤としての４−（１Ｈ−インダゾール−５−イル］アミノ）キナゾリン化合物
CA2644494A1 (en) * 2006-03-03 2007-09-13 Aveo Pharmaceuticals, Inc. Processes for synthesizing 7-alkynyl-4-aminoquinazolines and a related intermediate
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2009138781A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
AU2011229542A1 (en) * 2010-03-16 2012-11-08 Merck Patent Gmbh Morpholinylquinazolines
KR20220031732A (ko) * 2011-03-04 2022-03-11 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102918029B (zh) * 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
CN104203924B (zh) 2012-01-13 2019-06-11 艾森生物科学公司 杂环化合物及其作为抗癌药的用途
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CN103254143B (zh) * 2013-04-26 2015-10-07 浙江工业大学 4-[4-(2-二乙氨基乙酰氨基)苯胺基]-6-取代喹唑啉类化合物及制备和应用
CN104119350B (zh) 2013-04-28 2017-04-12 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
DK3019496T3 (da) 2013-07-11 2019-12-09 Acea Therapeutics Inc Pyrimidinderivater som kinaseinhibitorer
MX2018004332A (es) 2015-10-09 2019-01-10 Acea Therapeutics Inc Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas.
EP3574906B1 (en) * 2017-01-30 2024-07-03 Shionogi & Co., Ltd. Solid preparation comprising quinazoline derivative
JP2020516682A (ja) 2017-04-07 2020-06-11 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼの薬学的な塩、物理的形態および組成物、ならびにその作製方法
CN110577514B (zh) * 2018-06-08 2022-07-05 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
WO2019233459A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
KR20220047810A (ko) * 2019-08-15 2022-04-19 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 알키닐 퀴나졸린 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134236B2 (ja) 1992-01-30 2001-02-13 株式会社林原生物化学研究所 α−グリコシル−Ｌ−アスコルビン酸高含有物の製造方法とその製造のための分離システム
JP2994165B2 (ja) 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
JP4044839B2 (ja) * 2000-06-22 2008-02-06 ファイザー・プロダクツ・インク 異常細胞増殖を治療するための置換２環式誘導体
CA2547284A1 (en) * 2003-11-28 2005-06-09 Mitsubishi Pharma Corporation Quinazoline derivative and process for producing the same

Also Published As

Publication number Publication date
JP4285996B2 (ja) 2009-06-24
CA2442742A1 (en) 2002-08-29
WO2002066445A1 (en) 2002-08-29
JPWO2002066445A1 (ja) 2004-06-17
KR20030086269A (ko) 2003-11-07
TWI309647B (OSRAM) 2009-05-11
US20040116422A1 (en) 2004-06-17
EP1369418B1 (en) 2010-07-28
KR100861486B1 (ko) 2008-10-02
EP1369418A1 (en) 2003-12-10
EP1369418A4 (en) 2005-09-14
US20070265260A1 (en) 2007-11-15
CN1492860A (zh) 2004-04-28
US7294629B2 (en) 2007-11-13
CN1264824C (zh) 2006-07-19
ATE475652T1 (de) 2010-08-15

Similar Documents

Publication Publication Date Title
ATE475652T1 (de) Chinazolinderivate
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
BRPI0209216B8 (pt) derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
DE69528005D1 (de) Prolineamid-Derivate
EA200500508A1 (ru) Диариловые эфиры в качестве антагониста опиоидного рецептора
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
ATE450533T1 (de) Carboxamidderivate
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20051263L (no) Ny anvendelse av benzotiazolderivater
EA200801308A1 (ru) Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик
DK1465625T3 (da) Opløste topoisomerase-gifte
BRPI0417714A (pt) composto, composição farmacêutica, e, uso de um composto
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
NO20032261D0 (no) Medisinske preparater
NO20052698L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
ATE390923T1 (de) Topoisomerase-giftmittel
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon
ATE287397T1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
ATE293961T1 (de) Verwendung von hydantoin und seinen derivaten gegen hypalbuminämie
SE9900190D0 (sv) New compounds
SE0301371D0 (sv) New Compounds
DE60211866D1 (de) Thiophen substituierte amin derivate als glyt-1 inhibitoren